BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 11310635)

  • 1. Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis.
    Stefan K; Kunesch E; Benecke R; Classen J
    Ann Neurol; 2001 Apr; 49(4):536-9. PubMed ID: 11310635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis.
    Vucic S; Lin CS; Cheah BC; Murray J; Menon P; Krishnan AV; Kiernan MC
    Brain; 2013 May; 136(Pt 5):1361-70. PubMed ID: 23616585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis.
    Sommer M; Tergau F; Wischer S; Reimers CD; Beuche W; Paulus W
    J Neurol; 1999 Nov; 246 Suppl 3():III22-6. PubMed ID: 10631657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cortical silent period and amyotrophic lateral sclerosis.
    Prout AJ; Eisen AA
    Muscle Nerve; 1994 Feb; 17(2):217-23. PubMed ID: 8114792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adverse efects of riluzole (Rilutek) in the treatment of amyotrophic lateral sclerosis].
    Roch-Torreilles I; Camu W; Hillaire-Buys D
    Therapie; 2000; 55(2):303-12. PubMed ID: 10967703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
    Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
    Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.
    Traynor BJ; Alexander M; Corr B; Frost E; Hardiman O
    J Neurol; 2003 Apr; 250(4):473-9. PubMed ID: 12700914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients.
    Iłzecka J; Stelmasiak Z; Solski J; Wawrzycki S; Szpetnar M
    Neurol Sci; 2003 Nov; 24(4):290-2. PubMed ID: 14658053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis.
    Vucic S; Kiernan MC
    Clin Neurophysiol; 2008 May; 119(5):1088-96. PubMed ID: 18313980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyotrophic lateral sclerosis associated with pregnancy.
    Tyagi A; Sweeney BJ; Connolly S
    Neurol India; 2001 Dec; 49(4):413-4. PubMed ID: 11799421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An association study of riluzole serum concentration and survival and disease progression in patients with ALS.
    Groeneveld GJ; van Kan HJ; Lie-A-Huen L; Guchelaar HJ; van den Berg LH
    Clin Pharmacol Ther; 2008 May; 83(5):718-22. PubMed ID: 17898704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ALS/MND prevalence in Sweden estimated by riluzole sales statistics.
    Nygren I; Antonova K; Mattsson P; Askmark H
    Acta Neurol Scand; 2005 Mar; 111(3):180-4. PubMed ID: 15691287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
    Dib M
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor cortex abnormalities in amyotrophic lateral sclerosis with transcranial direct-current stimulation.
    Quartarone A; Lang N; Rizzo V; Bagnato S; Morgante F; Sant'angelo A; Crupi D; Battaglia F; Messina C; Girlanda P
    Muscle Nerve; 2007 May; 35(5):620-4. PubMed ID: 17221883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis.
    Vucic S; Cheah BC; Kiernan MC
    Exp Neurol; 2009 Nov; 220(1):177-82. PubMed ID: 19716820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three soccer playing friends with simultaneous amyotrophic lateral sclerosis.
    Wicks P; Ganesalingham J; Collin C; Prevett M; Leigh NP; Al-Chalabi A
    Amyotroph Lateral Scler; 2007 Jun; 8(3):177-9. PubMed ID: 17538780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)].
    Yanagisawa N; Shindo M
    Rinsho Shinkeigaku; 1996 Dec; 36(12):1329-30. PubMed ID: 9128396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What has changed with riluzole?
    Meininger V; Lacomblez L; Salachas F
    J Neurol; 2000 Dec; 247():19-22. PubMed ID: 11200701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety of riluzole in amyotrophic lateral sclerosis.
    Lacomblez L; Bensimon G; Leigh PN; Debove C; Bejuit R; Truffinet P; Meininger V;
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Mar; 3(1):23-9. PubMed ID: 12061945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.